Sanofi Genzyme, a speciality care global business unit of Sanofi, a bio pharmaceutical firm, has launched its multiple sclerosis treatment drug Aubagio in India.
It will help patients diagnosed with multiple sclerosis.
“For over a decade Sanofi has invested in developing and delivering novel therapeutic solutions for treatment of multiple sclerosis around the world; and is now bringing Aubagio, our original research product to India, said Sanofi India, MD, N Rajaram.
The medicine has the potential to offer an effective and convenient treatment of just once a day oral tablet and injectable treatment option as well.
“Aubagio is a differentiated disease modifying therapy, that blocks the enzyme involved in multiplication of overactive immune cells, said Sanofi South Asia, Country Medical Director, Shalini Menon.
Currently, Aubagio has an international presence in more than 81 countries and it is also approved by the USFDA in 2012.
It is to be noted that multiple sclerosis is an autoimmune, debilitating disease of the nervous system that affects the spinal cord and brain.